Welcome to our dedicated page for Royalty Pharma Plc news (Ticker: RPRX), a resource for investors and traders seeking the latest updates and insights on Royalty Pharma Plc stock.
Royalty Pharma plc (Nasdaq: RPRX) is a biopharmaceutical royalty company that frequently announces transactions, portfolio updates and financial results, making its news flow particularly relevant for investors following royalty-based business models in healthcare. Founded in 1996, the company describes itself as the largest buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry, with a portfolio of royalties on more than 35 commercial products and numerous development-stage therapies.
News about Royalty Pharma often centers on new royalty acquisitions and funding agreements. Recent press releases have described transactions such as acquiring remaining royalty interests in Roche’s Evrysdi, purchasing a royalty interest in Alnylam’s AMVUTTRA from Blackstone Life Sciences, and securing royalty interests in Nuvalent’s neladalkib and zidesamtinib. The company also reports synthetic royalty funding agreements, including a deal with Denali Therapeutics based on future net sales of tividenofusp alfa and a funding agreement with Teva for the anti-IL-15 antibody TEV-‘408 for vitiligo and celiac disease.
Royalty Pharma’s news feed additionally includes quarterly financial results, Portfolio Receipts updates, capital deployment figures, debt offerings, dividend declarations and participation in investor conferences. The company highlights clinical and regulatory milestones across its royalty portfolio, such as FDA approvals, Phase 3 trial initiations and pivotal data readouts for therapies like daraxonrasib, litifilimab, pelacarsen and other late-stage candidates.
Investors and observers who follow RPRX news can use these updates to track how the royalty portfolio is evolving, which therapeutic areas are gaining exposure, and how capital is being allocated across approved and investigational products. Regular news also provides insight into Royalty Pharma’s views on the royalty funding market, its use of non-GAAP liquidity measures, and its approach to shareholder returns through dividends and share repurchases.
Royalty Pharma (RPRX) has completed the monetization of MorphoSys Development Funding Bonds, receiving $511 million in upfront cash. Combined with previous payments, this brings total proceeds to $530 million on their original $300 million investment made in September 2022.
The monetization was executed at a 5.35% discount rate, following Novartis' acquisition of MorphoSys. Prior to this transaction, RPRX received two quarterly payments of $9.7 million each in Q4 2024 and January 2025. The company plans to reinvest the proceeds into share repurchases and new royalty acquisitions as part of their updated capital allocation strategy.
The Development Funding Bonds were part of a larger 2021 strategic partnership where RPRX provided up to $2.025 billion for MorphoSys' acquisition of Constellation Pharmaceuticals, including royalties on Tremfya and other development-stage assets.
Royalty Pharma (Nasdaq: RPRX) has scheduled its fourth quarter and full year 2024 financial results announcement for Tuesday, February 11, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day. Investors can access the conference call details and live webcast through the company's website investor relations section. A replay of both the call and webcast will remain available on the website for a minimum of 30 days.
Royalty Pharma (RPRX) expects 2024 Portfolio Receipts of approximately $2.8 billion, reaching the upper end of guidance, driven by ~13% year-over-year growth in Royalty Receipts. The company deployed $2.8 billion in royalty transactions during 2024, including a record year for synthetic royalty deals at $925 million.
The company's development-stage pipeline, comprising over 40 projects, has the potential to generate peak royalties exceeding $1.2 billion annually. This is based on projected un-risk adjusted peak sales of over $21 billion for potential therapies in the late-stage pipeline.
In 2025, Royalty Pharma will benefit from several new product launches, including Voranigo, Yorvipath, Niktimvo, Rytelo, and Cobenfy. The company expects Adjusted EBITDA of $2,560-2,570 million and Portfolio Cash Flow of $2,450-2,455 million for full year 2024.
Royalty Pharma (RPRX) announced two major initiatives to enhance shareholder value: the acquisition of its external manager, RP Management, , and a new $3 billion share repurchase program. The internalization transaction will generate significant cash savings exceeding $100 million in 2026 and $175 million in 2030, with cumulative savings of over $1.6 billion over ten years.
The acquisition involves approximately 24.5 million shares of Royalty Pharma equity vesting over 5-9 years, $100 million in cash, and assuming $380 million of existing Manager debt. The total transaction value is approximately $1.1 billion. The company plans to repurchase $2 billion of shares in 2025, subject to market conditions.
The integration will simplify corporate structure, enhance governance, ensure management continuity, and increase economic returns on investments. Royalty Pharma maintains its commitment to mid-single digit annual dividend growth and investment grade credit rating.
Royalty Pharma (RPRX) has announced a 5% increase in its quarterly dividend for the first quarter of 2025. The company will pay a dividend of $0.22 per Class A ordinary share, up from the previous quarter's dividend. The payment is scheduled for March 10, 2025, and shareholders must be on record by the close of business on February 21, 2025 to receive the dividend.
Royalty Pharma (Nasdaq: RPRX) has announced its participation in two major healthcare investor conferences in December 2024. The company will present at the 7th Annual Evercore ISI HealthCONx Conference on December 3 at 12:55 p.m. ET, followed by Citi's 2024 Global Healthcare Conference on December 4 at 1:45 p.m. ET. Both presentations will be available via webcast on the company's investor relations website and will remain archived for at least thirty days.
Royalty Pharma (Nasdaq: RPRX) has awarded its inaugural Prize for Impact in Healthcare to Michael Milken, founder of the Milken Institute, Faster Cures, and the Prostate Cancer Foundation. The prize includes a $250,000 charitable donation to support medical research initiatives. Milken's Prostate Cancer Foundation has raised over $1 billion since 1993, supporting 2,240 research projects across 245 cancer centers in 28 countries, leading to FDA approval of six new drugs for advanced prostate cancer. The foundation's work has contributed to declining prostate cancer mortality rates over the past two decades.
Royalty Pharma (RPRX) has announced the acquisition of a synthetic royalty on U.S. sales of RYTELO from Geron for $125 million in cash upfront. RYTELO, FDA-approved in June 2024 for treating low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia, will generate tiered royalty payments ranging from 7.75% on annual net sales up to $500 million, 3.0% on sales between $500 million-$1 billion, and 1.0% on sales over $1 billion. The agreement includes provisions for royalty payment cessation based on multiple thresholds of the initial investment.
Royalty Pharma (RPRX) reported strong Q3 2024 results with Portfolio Receipts growing 15% to $735 million and net cash from operations reaching $704 million. The company deployed approximately $1.2 billion in capital during the quarter and raised its full-year 2024 guidance, now expecting Portfolio Receipts between $2,750-$2,800 million. Notable achievements include acquiring royalties on three innovative therapies and FDA approvals for Cobenfy, Tremfya, and Voranigo. The company's performance was driven by strong growth from products including Trelegy, Evrysdi, cystic fibrosis franchise, and Tremfya.
Royalty Pharma has entered into a $350 million synthetic royalty funding agreement with Syndax Pharmaceuticals based on U.S. net sales of Niktimvo. Under the agreement, Syndax will receive an upfront payment in exchange for a 13.8% royalty on U.S. net sales, with payments ceasing upon reaching a 2.35x multiple. The funding is expected to support Niktimvo's upcoming launches and development, with Syndax's proforma cash approaching $800 million as of June 30. Niktimvo is positioned as a first-in-class product targeting chronic graft-versus-host disease (GVHD) treatment.
FAQ
What is the current stock price of Royalty Pharma Plc (RPRX)?
What is the market cap of Royalty Pharma Plc (RPRX)?
